SHR-A1904
- Generic Name
- SHR-A1904
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Phase 2
Not yet recruiting
- Conditions
- Gastric CancerHER2 + Gastric CancerPD-L1 PositiveCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 140
- Registration Number
- NCT06881017
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 3
Recruiting
- Conditions
- Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Paclitaxel, Docetaxel, Irinotecan
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 524
- Registration Number
- NCT06649292
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT05277168
- Locations
- 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States
🇺🇸LSU Health Sciences Center, New Orleans, Louisiana, United States
A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT04928625
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT04877717
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath